Company Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
265.6 USD +0.05% Intraday chart for Amgen Inc. -1.75% -7.77%

Business Summary

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:

- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;

- other (5.8%): primarily royalties.

The United States account for 70.3% of net sales.

Number of employees: 26,700

Sales per Business

USD in Million2022Weight2023Weight Delta
Human Therapeutics
95.5 %
24,801 94.2 % 26,910 95.5 % +8.50%
Other
4.5 %
1,522 5.8 % 1,280 4.5 % -15.90%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
70.3 %
18,595 70.6 % 19,806 70.3 % +6.51%
Rest of World
29.6 %
7,655 29.1 % 8,337 29.6 % +8.91%
Canada
0.2 %
73 0.3 % 47 0.2 % -35.62%

Managers

Managers TitleAgeSince
Chief Executive Officer 61 06-05-31
Director of Finance/CFO 65 19-10-22
Chief Tech/Sci/R&D Officer 52 Dec. 17
Chief Tech/Sci/R&D Officer 53 -
Chief Operating Officer 56 06-12-31
Compliance Officer 56 14-12-31
Chief Tech/Sci/R&D Officer - 00-12-31
Chief Tech/Sci/R&D Officer 61 04-12-31
Chief Tech/Sci/R&D Officer - 18-07-31
Chief Tech/Sci/R&D Officer 55 23-05-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 67 17-02-02
Director/Board Member 68 16-10-13
Director/Board Member 75 14-10-16
Director/Board Member 69 02-12-31
Director/Board Member 75 10-07-21
Chief Executive Officer 61 06-05-31
Director/Board Member 69 17-10-23
Director/Board Member 63 11-12-31
Director/Board Member 68 21-07-29
Director/Board Member 66 13-10-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 535,918,901 534,604,713 ( 99.75 %) 0 99.75 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.151 %
49,042,553 9.151 % 13 944 M $
BlackRock Advisors LLC
6.544 %
35,071,116 6.544 % 9 971 M $
29,463,970 5.498 % 8 377 M $
PRIMECAP Management Co.
2.723 %
14,591,468 2.723 % 4 149 M $
Eaton Vance Management
2.693 %
14,434,061 2.693 % 4 104 M $
Geode Capital Management LLC
2.303 %
12,339,956 2.303 % 3 508 M $
ishares (DE) Invag Mit Teilgesellschaftsvermogen
2.185 %
11,711,407 2.185 % 3 330 M $
Charles Schwab Investment Management, Inc.
1.939 %
10,393,110 1.939 % 2 955 M $
Wells Fargo Bank NA
1.766 %
9,463,053 1.766 % 2 691 M $
Lee Munder Investments Ltd.
1.321 %
7,080,253 1.321 % 2 013 M $
NameEquities%Valuation
Safra Asset Management Ltda.
0.000460 %
69,000 0.000460 % 695 300 $
Bram Bradesco Asset Management S/A DTVM
0.000230 %
34,524 0.000230 % 347 892 $
BB Gestão de Recursos DTVM SA
0.000221 %
33,151 0.000221 % 334 056 $

Holdings

NameEquities%Valuation
246,269,426 19.82% 2,992,444,422 $
35,368,653 22.26% 486,318,979 $
4,910,000 5.50% 116,121,500 $
3,206,281 8.69% 10,933,418 $
100,993 0.67% 2,965,154 $

Company contact information

Amgen, Inc.

One Amgen Center Drive

91320-1799, Thousand Oaks

+805 447 1000

http://www.amgen.com
address Amgen Inc.(AMGN)

Group companies

NameCategory and Sector
Pharmaceuticals: Major
Biotechnology
Amgen Manufacturing Ltd. (Bermuda)

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
265.5 USD
Average target price
304.5 USD
Spread / Average Target
+14.67%
Consensus